OVID
Ovid TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The balance sheet is now much stronger, with management saying the company should be funded into 2029, while OV329 has encouraging safety/PK and OV4071 has started in humans. If the next few clinical updates stay clean, the market could reward the stock for having multiple shots on goal.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Coverage is thin, so there is little sell-side validation or estimate revision support to anchor the upside case.
Momentum
93
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.70 · Bull $4.60 · Bear $1.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.23
Why
Momentum93 · Δ7d -
Value41 · Δ7d +0.1
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
69
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 92.8 / Value 41.1 / Sentiment 68.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$477.8M
Beta
0.26
Shares Out
130.18M
P/E (TTM) · Derived
-9.9
P/S (TTM)
32.69
P/FCF (TTM) · Derived
-6.88
Rev YoY
-23.7%
EPS YoY
+13.4%
Gross Margin
-
Op Margin
-618.3%
Net Debt
-$53.08M
Current Ratio
4.24
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology